Brian M. Culley Buys 40,000 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Stock

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) CEO Brian M. Culley bought 40,000 shares of the company's stock in a transaction dated Thursday, November 21st. The stock was bought at an average cost of $0.60 per share, with a total value of $24,000.00. Following the transaction, the chief executive officer now directly owns 194,842 shares in the company, valued at approximately $116,905.20. The trade was a 25.83 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Lineage Cell Therapeutics Stock Performance

Lineage Cell Therapeutics stock traded down $0.10 during mid-day trading on Friday, hitting $0.50. The company's stock had a trading volume of 15,606,529 shares, compared to its average volume of 1,090,486. Lineage Cell Therapeutics, Inc. has a twelve month low of $0.50 and a twelve month high of $1.61.

Wall Street Analyst Weigh In

Separately, Craig Hallum began coverage on Lineage Cell Therapeutics in a research note on Tuesday, August 20th. They issued a "buy" rating and a $4.00 target price for the company.

Institutional Investors Weigh In On Lineage Cell Therapeutics

Several hedge funds have recently made changes to their positions in LCTX. Raffles Associates LP increased its position in Lineage Cell Therapeutics by 35.8% in the 2nd quarter. Raffles Associates LP now owns 4,357,781 shares of the company's stock worth $4,346,000 after purchasing an additional 1,147,800 shares during the last quarter. Comerica Bank lifted its stake in shares of Lineage Cell Therapeutics by 84,745.8% in the 1st quarter. Comerica Bank now owns 250,295 shares of the company's stock valued at $370,000 after purchasing an additional 250,000 shares during the last quarter. Barclays PLC boosted its holdings in Lineage Cell Therapeutics by 311.3% in the third quarter. Barclays PLC now owns 211,300 shares of the company's stock worth $192,000 after purchasing an additional 159,924 shares in the last quarter. Bank of New York Mellon Corp increased its position in Lineage Cell Therapeutics by 35.7% during the second quarter. Bank of New York Mellon Corp now owns 435,958 shares of the company's stock worth $435,000 after buying an additional 114,762 shares during the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in Lineage Cell Therapeutics in the 3rd quarter worth approximately $84,000. Hedge funds and other institutional investors own 62.47% of the company's stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.